XML 86 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Balance Sheet Components - Additional Information (Detail)
3 Months Ended 9 Months Ended
Dec. 31, 2019
USD ($)
Milestone
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Schedule of Available-for-sale Securities [Line Items]              
Cash and cash equivalents $ 126,266,000 $ 532,468,000   $ 532,468,000      
Contractual maturities of available-for-sale investments       1 year      
Other-than-temporary impairment loss   0 $ 0 $ 0 $ 0    
Provision to write-down excess and obsolete inventory     $ 0   $ 0    
Number of regulatory milestones | Milestone 2            
Unbilled contract assets $ 180,000,000 0   0      
Billed contract assets             $ 50,000,000.0
API product price change in estimated variable consideration 36,324,000 3,957,000   3,957,000      
API product price adjustment 36,324,000 3,957,000   3,957,000      
Accrued long term co promotion liability current   14,800,000   14,800,000      
Accrued long-term co-promotion expenses 53,071,000 26,344,000   26,344,000      
Europe [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Unbilled contract assets           $ 130,000,000.0  
Astellas Agreement [Member] | Europe [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Unbilled contract assets 130,000,000.0            
Billed contract assets           $ 130,000,000  
AstraZeneca Agreements [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Unbilled contract assets             $ 50,000,000.0
Accrued long term co promotion liability current   14,800,000   14,800,000      
Reversal of previously accrued long-term co-promotion expenses   84,400,000          
AstraZeneca Agreements [Member] | Long-Term Liabilities [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Accrued long-term co-promotion expenses   26,300,000   26,300,000      
AstraZeneca Agreements [Member] | U.S./RoW [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Unbilled contract assets 50,000,000.0            
Foreign subsidiaries [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Cash and cash equivalents $ 11,900,000 $ 51,200,000   $ 51,200,000